Loading...
Agios Pharmaceuticals, Inc.
AGIO•NASDAQ
Healthcare
Biotechnology
$37.20
$-2.80(-7.00%)
Agios Pharmaceuticals, Inc. (AGIO) Financial Performance & Income Statement Overview
Review Agios Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
36.07%
↑ 36.07%
Operating Income Growth
-8.75%
↓ 8.75%
Net Income Growth
291.35%
↑ 291.35%
Operating Cash Flow Growth
-31.68%
↓ 31.68%
Operating Margin
-1188.86%
↓ 1188.86%
Gross Margin
83.22%
↑ 83.22%
Net Profit Margin
1798.26%
↑ 1798.26%
ROE
50.31%
↑ 50.31%
ROIC
-29.29%
↓ 29.29%
Agios Pharmaceuticals, Inc. (AGIO) Income Statement & Financial Overview
Review Agios Pharmaceuticals, Inc.'s (AGIO) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $8.73M | $10.73M | $8.96M | $8.62M |
| Cost of Revenue | $1.08M | $1.26M | $783000.00 | $3.09M |
| Gross Profit | $7.64M | $9.47M | $8.18M | $5.53M |
| Gross Profit Ratio | $0.88 | $0.88 | $0.91 | $0.64 |
| R&D Expenses | $72.74M | $82.81M | $72.45M | $75.81M |
| SG&A Expenses | $41.53M | $51.70M | $38.54M | $35.54M |
| Operating Expenses | $114.27M | $134.51M | $110.99M | $111.34M |
| Total Costs & Expenses | $115.36M | $135.77M | $111.78M | $114.43M |
| Interest Income | $0.00 | $18.02M | $13.06M | $8.12M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $1.37M | $1.34M | $1.59M |
| EBITDA | -$106.63M | -$123.67M | -$102.81M | -$104.22M |
| EBITDA Ratio | -$12.22 | -$11.53 | -$11.47 | -$12.10 |
| Operating Income | -$106.63M | -$125.04M | -$102.81M | -$105.82M |
| Operating Income Ratio | -$12.22 | -$11.65 | -$11.47 | -$12.28 |
| Other Income/Expenses (Net) | $17.34M | $19.64M | $1.10B | $9.70M |
| Income Before Tax | -$89.29M | -$105.40M | $1.001B | -$96.12M |
| Income Before Tax Ratio | -$10.23 | -$9.82 | $111.67 | -$11.16 |
| Income Tax Expense | $0.00 | -$8.88M | $53.12M | $0.00 |
| Net Income | -$89.29M | -$96.52M | $947.91M | -$96.12M |
| Net Income Ratio | -$10.23 | -$9.00 | $105.75 | -$11.16 |
| EPS | -$1.55 | -$1.70 | $16.65 | -$1.69 |
| Diluted EPS | -$1.55 | -$1.67 | $16.22 | -$1.69 |
| Weighted Avg Shares Outstanding | $57.46M | $57.16M | $56.94M | $56.80M |
| Weighted Avg Shares Outstanding (Diluted) | $57.46M | $57.16M | $58.43M | $56.80M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan